Xencor

$48.50
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

+$0.15 (+0.31%) Today

$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Xencor and other stocks, options, and ETFs commission-free!

About XNCR

Xencor, Inc. engages in the development of engineered monoclonal antibody therapeutics to treat severe and life-threatening diseases. Its proprietary technology platform, XmAb, is used to create next-generation antibody product candidates designed to treat autoimmune and allergic diseases, cancer, and other conditions. The company was founded by Bassil I. Dahiyat and Stephen L. Mayo in August 1997 and is headquartered in Monrovia, CA. The listed name for XNCR is Xencor, Inc. Common Stock.

CEO

Bassil I. Dahiyat

Employees

166

Headquarters

Monrovia, California

Founded

1997

Market Cap

2.89B

Price-Earnings Ratio

—

Dividend Yield

—

Average Volume

228.10K

High Today

$54.99

Low Today

$47.59

Open Price

$54.99

Volume

302.57K

52 Week High

$55.33

52 Week Low

$19.35

XNCR News

BenzingaFeb 23

Recap: Xencor Q4 Earnings

Shares of Xencor (NASDAQ:XNCR) increased in after-market trading after the company reported Q4 results. Quarterly Results Earnings per share rose 48.94% year

Analyst Ratings

82%

of 11 ratings

Buy

82%

Hold

Sell

XNCR Earnings

-$0.61

-$0.45

-$0.30

-$0.14

Q2 FY19

Q3 FY19

Q4 FY19

Q1 FY20

Q2 FY20

Q3 FY20

Q4 FY20

Estimated

-$0.38 per share

Actual

-$0.24 per share

Replay Earnings Call